Journal of Cancer Therapy
Vol.7 No.8(2016), Paper ID 69837, 8
pages
DOI:10.4236/jct.2016.78062
The Use of PSA Doubling Time to Predict Prognosis and the Use of PSA Response to Assess the Success for Prostate Cancer Patients Undergoing Docetaxel Chemotherapy
Sarp K. Keskin, Asif Yildirim, Cengiz Canakci, Ismail Ulus, Ramazan Gokhan Atis, Turhan Caskurlu
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, USA
Department of Urology, The University of Istanbul Medeniyet, Goztepe Training and Research Hospital, Istanbul, Turkey
Department of Urology, The University of Istanbul Medeniyet, Goztepe Training and Research Hospital, Istanbul, Turkey
Department of Urology, The University of Istanbul Medeniyet, Goztepe Training and Research Hospital, Istanbul, Turkey
Department of Urology, The University of Istanbul Medeniyet, Goztepe Training and Research Hospital, Istanbul, Turkey
Department of Urology, The University of Istanbul Medeniyet, Goztepe Training and Research Hospital, Istanbul, Turkey
Copyright © 2016 Sarp K. Keskin, Asif Yildirim, Cengiz Canakci, Ismail Ulus, Ramazan Gokhan Atis, Turhan Caskurlu et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Keskin, S. , Yildirim, A. , Canakci, C. , Ulus, I. , Atis, R. and Caskurlu, T. (2016) The Use of PSA Doubling Time to Predict Prognosis and the Use of PSA Response to Assess the Success for Prostate Cancer Patients Undergoing Docetaxel Chemotherapy.
Journal of Cancer Therapy,
7, 593-599. doi:
10.4236/jct.2016.78062.